<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Path Economics</title>
	<atom:link href="https://patheconomics.com/feed/" rel="self" type="application/rss+xml" />
	<link>https://patheconomics.com</link>
	<description>Path Economic Solutions Company</description>
	<lastBuildDate>Mon, 17 Feb 2025 21:32:16 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://patheconomics.com/wp-content/uploads/2024/08/Logo-Website-06-150x150.png</url>
	<title>Path Economics</title>
	<link>https://patheconomics.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Evidence Generation and Synthesis Methods in Health Technology Assessment (HTA) Workshop!</title>
		<link>https://patheconomics.com/hta-workshop/</link>
					<comments>https://patheconomics.com/hta-workshop/#respond</comments>
		
		<dc:creator><![CDATA[root]]></dc:creator>
		<pubDate>Mon, 17 Feb 2025 19:38:22 +0000</pubDate>
				<category><![CDATA[Events]]></category>
		<guid isPermaLink="false">https://patheconomics.com/?p=985</guid>

					<description><![CDATA[Event Details: Saudi Arabia Concludes Landmark Health Technology Assessment (HTA) Workshop with Global Experts DATE: 📅 February 8-12, 2025 LOCATION: 📍 Riyadh, Saudi Arabia Saudi Arabia successfully hosted the Health Technology Assessment (HTA) Workshop at Crowne Plaza Riyadh Palace from February 8 to 12, 2025, bringing together renowned global experts, policymakers, and researchers to advance [&#8230;]]]></description>
										<content:encoded><![CDATA[<p><span style="text-decoration: underline;"><strong><span style="font-family: georgia, palatino, serif; font-size: 14px;">Event Details:</span></strong></span></p>
<p><img decoding="async" class="wp-image-1038 aligncenter" src="https://patheconomics.com/wp-content/uploads/2025/02/cropped-Logo-1024x191-1.png" alt="" width="247" height="46" data-wp-editing="1" srcset="https://patheconomics.com/wp-content/uploads/2025/02/cropped-Logo-1024x191-1.png 1024w, https://patheconomics.com/wp-content/uploads/2025/02/cropped-Logo-1024x191-1-300x56.png 300w, https://patheconomics.com/wp-content/uploads/2025/02/cropped-Logo-1024x191-1-768x143.png 768w" sizes="(max-width: 247px) 100vw, 247px" /></p>
<p><strong><span style="font-family: georgia, palatino, serif; font-size: 14px;">Saudi Arabia Concludes Landmark Health Technology Assessment (HTA) Workshop with Global Experts</span></strong><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong>DATE:</strong> <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f4c5.png" alt="📅" class="wp-smiley" style="height: 1em; max-height: 1em;" /> February 8-12, 2025</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong>LOCATION:</strong> <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f4cd.png" alt="📍" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Riyadh, Saudi Arabia</span></p>
<p><span style="font-family: georgia, palatino, serif; font-size: 14px;">Saudi Arabia successfully hosted the <span style="text-decoration: underline;"><span style="color: #000000;"><a style="color: #000000; text-decoration: underline;" href="https://www.linkedin.com/posts/peorsaudi_hta-pharmacoeconomics-ispor-activity-7295501383477166080-0Mm_?utm_source=share&amp;utm_medium=member_desktop&amp;rcm=ACoAAAgPxIkBb_gDAt7izohCIZD94CZE6D-NbWc" target="_blank" rel="noopener">Health Technology Assessment (HTA) Workshop</a></span></span> at Crowne Plaza Riyadh Palace from February 8 to 12, 2025, bringing together renowned global experts, policymakers, and researchers to advance evidence-based healthcare decision-making. The event, hosted by <strong>King Saud University in collaboration with the Saudi Food and Drug Authority (SFDA), NICE International, and EuroQol</strong>, provided a crucial platform for discussing <strong>health economics, patient-centered care, and innovative policy strategies</strong>.</span></p>
<p><span style="font-family: georgia, palatino, serif; font-size: 14px;">The workshop featured distinguished speakers from <strong>Saudi Arabia, the United Kingdom, the United States, Canada, the Netherlands, Egypt, Spain, and Qatar</strong>, representing organizations such as:</span></p>
<p><span style="font-family: georgia, palatino, serif; font-size: 14px;">• NICE International (UK)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;">• EuroQol (Netherlands)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;">• Saudi Food and Drug Authority (SFDA)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;">• King Saud University (Saudi Arabia)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;">• Path Economics, LLC (USA)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;">• CCHO (UAE &amp; Canada)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;">• National Institute for Health and Care Excellence (NICE)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;">• ISPOR Qatar Chapter</span></p>
<p><strong><span style="font-family: georgia, palatino, serif; font-size: 14px;">Key Topics and Highlights:</span></strong><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;">Over five days, the workshop facilitated expert-led discussions, case studies, and real-world applications on critical areas, including:</span></p>
<p><span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2714.png" alt="✔" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Health Economics and Evidence-Based Decision-Making</strong> – Experts explored systematic reviews, meta-analysis techniques, and Cochrane risk assessments to strengthen healthcare evaluations.</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2714.png" alt="✔" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Artificial Intelligence and Real-World Data (RWD)</strong> – Sessions examined AI-driven data analysis and big data applications in healthcare decision-making.</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2714.png" alt="✔" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Patient-Centered Outcomes and the Saudi EQ-5D Value Set</strong> – Discussions focused on Patient-Reported Outcome Measures (PROMs) and their integration into healthcare policies, with a particular emphasis on the new EQ-5D Value Set for Saudi Arabia.</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2714.png" alt="✔" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Economic Evaluations in Healthcare</strong> – Participants analyzed Quality-Adjusted Life Years (QALYs), Disability-Adjusted Life Years (DALYs), and ISPOR guidelines for economic modeling.</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2714.png" alt="✔" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Budget Impact Model (BIM) Adaptation</strong> – A highlight of the event was the session led by Dr. Nimer Alkhatib, PhD, a globally recognized health economist and founder of Path Economics, LLC (USA). Dr. Alkhatib provided a step-by-step framework for adapting budget impact models in different disease areas, including oncology and diabetes, guiding policymakers on optimizing healthcare cost assessments.</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2714.png" alt="✔" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Managed Entry Agreements (MEA) and Outcome-Based Pricing</strong> – Discussions, led by Dr. Steve Williamson, Dr. Pilar Pinilla-Dominguez, and Dr. Dalia Dawoud, examined innovative pricing strategies for orphan medications and rare disease treatments.</span></p>
<p><strong><span style="font-family: georgia, palatino, serif; font-size: 14px;">Keynote Speakers and Moderators:</span></strong><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;">The event featured a prestigious lineup of experts, including:</span></p>
<p><strong><span style="font-family: georgia, palatino, serif; font-size: 14px;">Keynote Speakers:</span></strong><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong>• <span style="color: #000000; text-decoration: underline;"><a style="color: #000000; text-decoration: underline;" href="https://www.linkedin.com/in/nimer-alkhatib-5a7b8647/" target="_blank" rel="noopener">Dr. Nimer Alkhatib, PhD</a></span></strong> (Founder, Path Economics, LLC, USA)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong>• Dr. Steve Williamson, PhD</strong> (Associate Director, NICE International, UK)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong>• Dr. Pilar Pinilla-Dominguez, PhD</strong> (Associate Director, NICE International, Spain)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong>• Dr. Dalia Dawoud, PhD</strong> (Associate Director, NICE, Egypt)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong>• Dr. Richard Chapman, PhD</strong> (Chief Scientific Officer, Center of Innovation &amp; Value Research, USA)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong>• Dr. Fatima AlSayah, PhD</strong> (Principal &amp; PROMs Lead, CCHO, Canada)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong>• Dr. Elly Stolk, PhD</strong> (Scientific Director, EuroQol, Netherlands)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong>• Dr. Randa Attieh, PhD</strong> (Scientific Counselor, INESS, Canada)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong>• Dr. Howard Friedman, PhD</strong> (Chief Data Scientist, Columbia University, USA)</span></p>
<p><iframe title="Embedded post" src="https://www.linkedin.com/embed/feed/update/urn:li:share:7295160017027002368" width="504" height="572" frameborder="0" allowfullscreen="allowfullscreen"></iframe></p>
<p><strong><span style="font-family: georgia, palatino, serif; font-size: 14px;">Moderators:</span></strong><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong>• Dr. Abdulaali Almutairi, PhD</strong> (Senior Chief Drug Safety Expert, SFDA, Saudi Arabia)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong>• Dr. Bander Balkhi, PhD</strong> (Professor, King Saud University, Saudi Arabia)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong>• Dr. Anas Hamad, PhD</strong> (Director of Pharmacy, National Center for Cancer Care, Qatar)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong>• Dr. Omar Al Mohammed, PhD</strong> (Professor, King Saud University, Saudi Arabia)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong>• Dr. Yazed Alruthia, PhD</strong> (Professor, King Saud University, Saudi Arabia)</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong>• Dr. Christiane Maskineh, PhD</strong> (CEO, CCHO, UAE)</span></p>
<blockquote class="twitter-tweet" data-dnt="true">
<p dir="ltr" lang="en">You could feel the energy in every corner! <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f4a1.png" alt="💡" class="wp-smiley" style="height: 1em; max-height: 1em;" /><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f3a4.png" alt="🎤" class="wp-smiley" style="height: 1em; max-height: 1em;" /></p>
<p>The attendees at the <a href="https://twitter.com/hashtag/HTA?src=hash&amp;ref_src=twsrc%5Etfw">#HTA</a> workshop actively participated and engaged in dynamic discussions during Dr. Richard Chapman’s session! <a href="https://t.co/iM2423jwTR">pic.twitter.com/iM2423jwTR</a></p>
<p>— PEOR Society (@PEORSociety) <a href="https://twitter.com/PEORSociety/status/1889023693646602737?ref_src=twsrc%5Etfw">February 10, 2025</a></p></blockquote>
<p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p>
<p><strong><span style="font-family: georgia, palatino, serif; font-size: 14px;">Advancing Saudi Arabia’s Role in Health Technology Assessment:</span></strong><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;">With the support of King Saud University, SFDA, and international partners, this workshop solidified Saudi Arabia’s leadership in HTA and evidence-based healthcare policy. The discussions and collaborations made during the event will contribute to:</span></p>
<p><span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2705.png" alt="✅" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Optimizing healthcare expenditures</strong> through cost-effectiveness models.</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2705.png" alt="✅" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Enhancing patient access</strong> to life-saving medications and technologies.</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2705.png" alt="✅" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Driving AI-driven innovations</strong> in health technology assessment.</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><strong><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2705.png" alt="✅" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Shaping international best practices</strong> in health economics and policy.</span></p>
<p><span style="font-family: georgia, palatino, serif; font-size: 14px;">The HTA Workshop marked a significant step in <strong>Saudi Arabia’s Vision 2030</strong> <strong>initiative</strong>, emphasizing the importance of <strong>evidence-based policymaking to improve healthcare outcomes and system efficiency</strong>. The event successfully fostered international collaboration, setting the stage for future <strong>policy innovations and strategic healthcare investments</strong>.</span></p>
<p><iframe title="Embedded post" src="https://www.linkedin.com/embed/feed/update/urn:li:ugcPost:7297184450138800129?compact=1" width="710" height="399" frameborder="0" allowfullscreen="allowfullscreen"></iframe></p>
<p><span style="font-family: georgia, palatino, serif; font-size: 14px;">_____________</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;">Useful Resources:</span><br />
<span style="font-family: georgia, palatino, serif; font-size: 14px;"><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f4e9.png" alt="📩" class="wp-smiley" style="height: 1em; max-height: 1em;" /> <a href="mailto:info@patheconomics.com">info@patheconomics.com</a></span></p>
<p><img loading="lazy" decoding="async" class="alignnone size-full wp-image-1020" src="https://patheconomics.com/wp-content/uploads/2025/02/linkedin.png" alt="" width="16" height="16" /> <span style="font-family: georgia, palatino, serif; font-size: 14px;"><a href="https://www.linkedin.com/company/peorsaudi/?viewAsMember=true" target="_blank" rel="noopener">Pharmacoeconomics and Outcomes Research Saudi Society (PEOR)</a></span></p>
<p><img loading="lazy" decoding="async" class="alignnone size-full wp-image-1044" src="https://patheconomics.com/wp-content/uploads/2025/02/twitter.png" alt="" width="16" height="16" /> <a href="https://x.com/sa_ispor" target="_blank" rel="noopener"><span style="font-size: 14px;">ISPOR Saudi Arabia</span></a></p>
<p><span style="font-family: georgia, palatino, serif; font-size: 14px;"><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f30d.png" alt="🌍" class="wp-smiley" style="height: 1em; max-height: 1em;" /> <a href="https://ispor-saudi.com/" target="_blank" rel="noopener">ISPOR Saudi Arabia</a></span></p>
]]></content:encoded>
					
					<wfw:commentRss>https://patheconomics.com/hta-workshop/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Upcoming ISPOR Europe 2024 17-20 November</title>
		<link>https://patheconomics.com/upcoming-ispor-europe-2024-17-20-november/</link>
					<comments>https://patheconomics.com/upcoming-ispor-europe-2024-17-20-november/#respond</comments>
		
		<dc:creator><![CDATA[root]]></dc:creator>
		<pubDate>Mon, 26 Aug 2024 18:33:48 +0000</pubDate>
				<category><![CDATA[Events]]></category>
		<category><![CDATA[ISPOREurope]]></category>
		<category><![CDATA[PathEconomics]]></category>
		<guid isPermaLink="false">https://patheconomics.com/?p=753</guid>

					<description><![CDATA[Event Details:  DATE: November 17, 2024 &#8211; November 20, 2024 WEBSITE: ISROP EUROE 2024 LOCATION: Barcelona, Spain &#160; Overview ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed [&#8230;]]]></description>
										<content:encoded><![CDATA[<p dir="ltr"><span style="font-family: georgia, palatino, serif;"><span style="text-decoration: underline; color: #ff6600;">Event Details:</span> </span></p>
<p dir="ltr"><span style="font-family: georgia, palatino, serif;">DATE: <span style="font-size: 14px;">November 17, 2024 &#8211; November 20, 2024</span></span></p>
<p dir="ltr"><span style="font-family: georgia, palatino, serif;">WEBSITE: <a href="https://www.ispor.org/conferences-education/conferences/upcoming-conferences/ispor-europe-2024" target="_blank" rel="noopener"><span style="font-size: 14px;">ISROP EUROE 2024</span></a></span></p>
<p dir="ltr"><span style="font-family: georgia, palatino, serif;">LOCATION: <span style="font-size: 14px;">Barcelona, Spain</span></span></p>
<p>&nbsp;</p>
<table style="border-collapse: collapse; width: 100%;">
<tbody>
<tr>
<td dir="ltr" style="width: 54.5362%;" colspan="2">
<p style="text-align: justify;"><strong><span style="font-size: 16px; font-family: georgia, palatino, serif; color: #000000;">Overview</span></strong></p>
<p style="text-align: justify;"><span style="font-size: 16px; font-family: georgia, palatino, serif; color: #000000;">ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.</span></p>
<p style="text-align: justify;"><span style="font-size: 16px; font-family: georgia, palatino, serif; color: #000000;">ISPOR’s community of 14,000 individual and chapter members representing more than 100 countries engages a wide variety of healthcare stakeholders, including researchers and academicians, assessors and regulators, payers and policy makers, the life sciences industry, healthcare providers, and patient engagement organizations. The Society’s leadership has served as an unbiased resource and catalyst for innovation in the field for more than 25 years.</span></p>
</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<table style="border-collapse: collapse; width: 100%;">
<tbody>
<tr>
<td dir="ltr" style="width: 62.0122%;"><strong><span style="font-family: georgia, palatino, serif;">ISPOR’s Global Stakeholders</span></strong></p>
<p style="text-align: justify;"><span style="font-family: georgia, palatino, serif;">ISPOR believes that by including a wide variety of stakeholder viewpoints, the Society can advance the science and increase the understanding and application of health economics and outcomes research (HEOR) methods to improve healthcare decisions. Learn more about our members <a href="https://www.ispor.org/about/our-members" target="_blank" rel="noopener">here</a>.</span></p>
</td>
<td dir="ltr" style="width: 37.9878%;">
<p style="text-align: center;"><a href="https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__custom_2K_Standard_r15_c2_.png" target="_blank" rel="noopener"><img loading="lazy" decoding="async" class="aligncenter wp-image-756 size-medium" src="https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__custom_2K_Standard_r15_c2_-300x224.png" alt="" width="300" height="224" srcset="https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__custom_2K_Standard_r15_c2_-300x224.png 300w, https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__custom_2K_Standard_r15_c2_-1024x764.png 1024w, https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__custom_2K_Standard_r15_c2_-768x573.png 768w, https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__custom_2K_Standard_r15_c2_-1536x1146.png 1536w, https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__custom_2K_Standard_r15_c2_.png 2048w" sizes="auto, (max-width: 300px) 100vw, 300px" /></a></p>
</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<table class=" alignleft" dir="ltr" style="width: 100%; border-collapse: collapse; height: 308px;">
<tbody>
<tr style="height: 38px;">
<td style="width: 44.7598%; height: 38px;"><span style="font-family: georgia, palatino, serif;"><strong>Our Contributions:</strong></span></td>
<td style="width: 9.82332%; height: 38px;"><span style="font-family: georgia, palatino, serif;"> </span></td>
<td style="width: 45.4168%; height: 38px;"><strong><span style="font-family: georgia, palatino, serif;"> </span></strong></td>
</tr>
<tr style="height: 98px;">
<td style="width: 44.7598%; height: 114px; text-align: left;"><span style="font-family: georgia, palatino, serif;">&#8211; In our collaboration with the Saudi Gastro Association and academic institutions in the kingdom of Saudi Arabia, we evaluated the Budget Impact Analysis of <strong>Subcutaneous Infliximab (CT-P13 SC)</strong> for Treating Inflammatory Bowel Disease in Saudi Arabia: Analysis from Payer Perspective.</span></td>
<td style="width: 9.82332%; height: 114px;"><span style="font-family: georgia, palatino, serif;"> </span></td>
<td style="width: 45.4168%; height: 114px; text-align: left;"><strong><span style="font-family: georgia, palatino, serif;">Path Economics is attending the ISPOR Europe 2024 to present this abstract on Tuesday, 19 November 2024 10:30 &#8211; 13:30.</span></strong></td>
</tr>
<tr style="height: 25px;">
<td style="width: 44.7598%; text-align: left; height: 25px;"><span style="font-family: georgia, palatino, serif;"> </span></td>
<td style="width: 9.82332%; height: 25px;"><span style="font-family: georgia, palatino, serif;"> </span></td>
<td style="width: 45.4168%; text-align: left; height: 25px;"><strong><span style="font-family: georgia, palatino, serif;"> </span></strong></td>
</tr>
<tr style="height: 159px;">
<td style="width: 44.7598%; height: 121px; text-align: left;"><span style="font-family: georgia, palatino, serif;">&#8211; Jointly with the Algerian Ministry of Health, we conducted a Cost-Effectiveness of <strong>Febuxostat 120/80 mg</strong> as a Second-Line after Allopurinol 100/300mg in Gout Patients in Algeria. </span></td>
<td style="width: 9.82332%; height: 121px;"><span style="font-family: georgia, palatino, serif;"> </span></td>
<th style="width: 45.4168%; text-align: left; vertical-align: middle; height: 121px;"><span style="font-family: georgia, palatino, serif;">Path Economics is attending the ISPOR Europe 2024 to present this abstract on Tuesday, 19 November 2024 16:00 &#8211; 19:00.</span></th>
</tr>
</tbody>
</table>
<p><a href="https://www.ispor.org/conferences-education/conferences/upcoming-conferences/ispor-europe-2024?utm_medium=referral&amp;utm_source=public&amp;utm_campaign=ispor_europe_2024&amp;utm_content=marketing-kit-ad_register" target="_blank" rel="noopener"><img loading="lazy" decoding="async" class="alignnone wp-image-803 size-full" src="https://patheconomics.com/wp-content/uploads/2024/08/PATHISPOREurop.png" alt="" width="2000" height="150" srcset="https://patheconomics.com/wp-content/uploads/2024/08/PATHISPOREurop.png 2000w, https://patheconomics.com/wp-content/uploads/2024/08/PATHISPOREurop-300x23.png 300w, https://patheconomics.com/wp-content/uploads/2024/08/PATHISPOREurop-1024x77.png 1024w, https://patheconomics.com/wp-content/uploads/2024/08/PATHISPOREurop-768x58.png 768w, https://patheconomics.com/wp-content/uploads/2024/08/PATHISPOREurop-1536x115.png 1536w" sizes="auto, (max-width: 2000px) 100vw, 2000px" /></a></p>
]]></content:encoded>
					
					<wfw:commentRss>https://patheconomics.com/upcoming-ispor-europe-2024-17-20-november/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Net-Monetory Budget Impact of Toripalimab in the US market</title>
		<link>https://patheconomics.com/net-monetory-budget-impact-of-toripalimab-in-the-us-market/</link>
					<comments>https://patheconomics.com/net-monetory-budget-impact-of-toripalimab-in-the-us-market/#respond</comments>
		
		<dc:creator><![CDATA[root]]></dc:creator>
		<pubDate>Fri, 23 Aug 2024 14:34:20 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://patheconomics.com/?p=714</guid>

					<description><![CDATA[In our collaboration with Matrix45 USA, we could estimate the savings on Medicare’s bill for the coverage of Toripalimab in metastatic nasopharyngeal carcinoma that was associated with 90% accumulative probability We are proud to be part of this assessment for the net monetary value of Toripalimab in the US market Check out: www.tandfonline.com &#160;]]></description>
										<content:encoded><![CDATA[<p style="direction: ltr;">In our collaboration with Matrix45 USA, we could estimate the savings on Medicare’s bill for the coverage of Toripalimab in metastatic nasopharyngeal carcinoma that was associated with 90% accumulative probability</p>
<p style="direction: ltr;">We are proud to be part of this assessment for the net monetary value of Toripalimab in the US market</p>
<p style="direction: ltr;">Check out: <a href="https://www.tandfonline.com/doi/full/10.1080/13696998.2024.2379055" target="_blank" rel="noopener">www.tandfonline.com</a></p>
<p>&nbsp;</p>
<p><a href="https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__none_2K_Standard_r_c_-5.jpeg" target="_blank" rel="noopener"><img loading="lazy" decoding="async" class="aligncenter wp-image-717 size-large" src="https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__none_2K_Standard_r_c_-5-1024x585.jpeg" alt="" width="1024" height="585" srcset="https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__none_2K_Standard_r_c_-5-1024x585.jpeg 1024w, https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__none_2K_Standard_r_c_-5-300x171.jpeg 300w, https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__none_2K_Standard_r_c_-5-768x439.jpeg 768w, https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__none_2K_Standard_r_c_-5.jpeg 1400w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /></a></p>
]]></content:encoded>
					
					<wfw:commentRss>https://patheconomics.com/net-monetory-budget-impact-of-toripalimab-in-the-us-market/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Market Access Training</title>
		<link>https://patheconomics.com/market-access-training/</link>
					<comments>https://patheconomics.com/market-access-training/#respond</comments>
		
		<dc:creator><![CDATA[root]]></dc:creator>
		<pubDate>Fri, 23 Aug 2024 14:18:27 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://patheconomics.com/?p=704</guid>

					<description><![CDATA[The Market Access Training for Professionals held be MS PHARMA was just a great 3-day program with hands-on exercises to tackle challenges and create opportunities for innovative products. Thanks to our organizing partner EthosTrend &#160;]]></description>
										<content:encoded><![CDATA[<p style="direction: ltr;">The Market Access Training for Professionals held be <a href="https://www.linkedin.com/company/ms-pharma/" target="_blank" rel="noopener">MS PHARMA</a> was just a great 3-day program with hands-on exercises to tackle challenges and create opportunities for innovative products.</p>
<p style="direction: ltr;">Thanks to our organizing partner <a href="https://www.linkedin.com/company/ethostrend/" target="_blank" rel="noopener">EthosTrend</a></p>
<p>&nbsp;</p>
<p style="padding-right: 160px;"><a href="https://patheconomics.com/wp-content/uploads/2024/08/PHOTO-2024-05-10-10-41-18.jpg" target="_blank" rel="noopener popup"><img loading="lazy" decoding="async" class="aligncenter wp-image-706 size-large" src="https://patheconomics.com/wp-content/uploads/2024/08/PHOTO-2024-05-10-10-41-18-1024x768.jpg" alt="" width="1024" height="768" srcset="https://patheconomics.com/wp-content/uploads/2024/08/PHOTO-2024-05-10-10-41-18-1024x768.jpg 1024w, https://patheconomics.com/wp-content/uploads/2024/08/PHOTO-2024-05-10-10-41-18-300x225.jpg 300w, https://patheconomics.com/wp-content/uploads/2024/08/PHOTO-2024-05-10-10-41-18-768x576.jpg 768w, https://patheconomics.com/wp-content/uploads/2024/08/PHOTO-2024-05-10-10-41-18-1536x1152.jpg 1536w, https://patheconomics.com/wp-content/uploads/2024/08/PHOTO-2024-05-10-10-41-18.jpg 1600w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /></a></p>
]]></content:encoded>
					
					<wfw:commentRss>https://patheconomics.com/market-access-training/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>The Hidden Economic Toll of Tobacco Smoking and Secondhand Smoke in Jordan</title>
		<link>https://patheconomics.com/the-hidden-economic-toll-of-tobacco-smoking-and-secondhand-smoke-in-jordan/</link>
					<comments>https://patheconomics.com/the-hidden-economic-toll-of-tobacco-smoking-and-secondhand-smoke-in-jordan/#respond</comments>
		
		<dc:creator><![CDATA[root]]></dc:creator>
		<pubDate>Thu, 22 Aug 2024 16:03:12 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[direct cost]]></category>
		<category><![CDATA[economic evaluation]]></category>
		<category><![CDATA[indirect costs]]></category>
		<category><![CDATA[Jordan]]></category>
		<category><![CDATA[productivity loss]]></category>
		<category><![CDATA[Smoking]]></category>
		<category><![CDATA[tobacco]]></category>
		<guid isPermaLink="false">https://patheconomics.com//?p=671</guid>

					<description><![CDATA[Article Source: Journal of Medical Economics, Volume 27, 2024 &#8211; Issue 1 Published online 02 Jul 2024 Authors: Nimer S. Alkhatib, Eman Massad, Omar Rashdan, Wendy Max, Shiraz Halloush, Hamza Abumansour, Ala’a Alkhatib, Reema A. Karasneh, Samah Al-Shatnawi, Tariq Qirim, Feras Hawari &#38; Said Alkhatib ================= Introduction Tobacco smoking is not just a personal health [&#8230;]]]></description>
										<content:encoded><![CDATA[<h5 style="direction: ltr;"><span style="color: #000000;">Article Source:</span> <a href="https://doi.org/10.1080/13696998.2024.2373002" target="_blank" rel="noopener">Journal of Medical Economics, Volume 27, 2024 &#8211; Issue 1</a></h5>
<h5 style="direction: ltr;"><span style="color: #000000;">Published online 02 Jul 2024</span></h5>
<p dir="ltr"><span style="color: #000000;"><strong>Authors:</strong> Nimer S. Alkhatib, Eman Massad, Omar Rashdan, Wendy Max, Shiraz Halloush, Hamza Abumansour, Ala’a Alkhatib, Reema A. Karasneh, Samah Al-Shatnawi, Tariq Qirim, Feras Hawari &amp; Said Alkhatib</span></p>
<p style="direction: ltr;">=================</p>
<h5 style="direction: ltr;"><span style="text-decoration: underline;"><span style="color: #000000;"><strong>Introduction</strong></span></span></h5>
<p style="direction: ltr;"><span style="color: #000000;">Tobacco smoking is not just a personal health issue; it has far-reaching economic consequences that affect entire nations. In Jordan, the economic impact of tobacco smoking and secondhand smoke exposure is staggering. While health concerns are often highlighted, the financial burden borne by the economy is equally alarming. This blog delves into the costs associated with tobacco use in Jordan, revealing how it strains the nation’s resources and what can be done to mitigate these impacts.</span></p>
<h5 style="direction: ltr;"><span style="text-decoration: underline;"><span style="color: #000000;"><strong>The Scope of the Problem</strong></span></span></h5>
<p style="direction: ltr;"><span style="color: #000000;">Jordan has one of the highest smoking rates in the region, with a significant portion of its population being active smokers. The pervasive culture of smoking extends beyond just cigarettes, with other forms of tobacco consumption also contributing to the overall impact. But the issue isn&#8217;t confined to smokers alone; non-smokers, including children and the elderly, are frequently exposed to secondhand smoke, leading to severe health complications.</span></p>
<h5 style="direction: ltr;"><span style="text-decoration: underline;"><span style="color: #000000;"><strong>Direct Costs: Healthcare Expenditures</strong></span></span></h5>
<p style="direction: ltr;"><span style="color: #000000;">One of the most direct economic impacts of tobacco use in Jordan is the substantial healthcare costs. Treating smoking-related diseases such as lung cancer, heart disease, and respiratory conditions consumes a large portion of the national healthcare budget. These expenditures include hospitalizations, medical treatments, medications, and ongoing care for chronic conditions. The cost to the healthcare system is exacerbated by the need for more advanced and prolonged treatments for illnesses caused by both active and passive smoking.</span></p>
<h5 style="direction: ltr;"><span style="text-decoration: underline;"><span style="color: #000000;"><strong>Indirect Costs: Lost Productivity and Mortality</strong></span></span></h5>
<p style="direction: ltr;"><span style="color: #000000;">The indirect costs of smoking are perhaps even more debilitating. The loss of productivity due to smoking-related illnesses, absenteeism, and premature deaths contributes significantly to the economic burden. Workers who are sick more frequently or die prematurely are less able to contribute to the economy, leading to a reduction in overall productivity. Additionally, the burden of caregiving for those suffering from smoking-related diseases often falls on family members, further reducing economic productivity.</span></p>
<p style="direction: ltr;"><span style="color: #000000;">Premature deaths not only affect the workforce but also lead to a loss of human capital. Skilled workers and professionals lost to smoking-related diseases leave gaps in the economy that are difficult to fill, especially in specialized fields. This loss has a ripple effect, impacting businesses and industries across the country.</span></p>
<h5 style="direction: ltr;"><span style="text-decoration: underline;"><span style="color: #000000;"><strong>The Burden on Families and Society</strong></span></span></h5>
<p style="direction: ltr;"><span style="color: #000000;">Families of smokers also bear significant costs, both financially and emotionally. The healthcare expenses for treating smoking-related diseases can be a heavy burden, especially for low-income families. Furthermore, the time spent caring for sick family members can lead to lost income and opportunities, trapping families in cycles of poverty.</span></p>
<p style="direction: ltr;"><span style="color: #000000;">Society as a whole also suffers from the broader impact of smoking. Public health campaigns, smoking cessation programs, and the enforcement of smoking bans all require resources that could otherwise be directed towards other pressing social issues. Moreover, the environmental impact of tobacco production and consumption further strains Jordan’s resources.</span></p>
<h5 style="direction: ltr;"><span style="text-decoration: underline;"><span style="color: #000000;"><strong>Addressing the Issue: A Path Forward</strong></span></span></h5>
<p style="direction: ltr;"><span style="color: #000000;">Reducing the economic burden of tobacco use in Jordan requires a multi-faceted approach. Strengthening public health campaigns to discourage smoking, enforcing stricter regulations on tobacco sales, and increasing taxes on tobacco products are essential steps. Additionally, improving access to smoking cessation programs and providing support for those who wish to quit can help reduce the number of smokers and, consequently, the associated costs.</span></p>
<p style="direction: ltr;"><span style="color: #000000;">Investing in public health initiatives that raise awareness about the dangers of secondhand smoke and promoting smoke-free environments in public spaces are also critical. By protecting non-smokers from the harmful effects of secondhand smoke, Jordan can reduce the overall healthcare burden and improve the quality of life for its citizens.</span></p>
<h5 style="direction: ltr;"><span style="text-decoration: underline;"><span style="color: #000000;"><strong>Conclusion</strong></span></span></h5>
<p style="direction: ltr;"><span style="color: #000000;">The economic impact of tobacco smoking and secondhand smoke exposure in Jordan is a pressing issue that demands urgent attention. While the health risks are well-documented, the financial costs are equally significant and cannot be ignored. By taking comprehensive action to reduce smoking rates and protect non-smokers, Jordan can alleviate the economic strain and create a healthier, more prosperous society for all.</span></p>
<p style="direction: ltr;">=================</p>
<p>Article DOI: 10.1080/13696998.2024.2373002<br />
Author name: Nimer S. Alkhatib, Eman Massad, Omar Rashdan, Wendy Max, Shiraz Halloush, Hamza Abumansour, Ala’a Alkhatib, Reema A. Karasneh, Samah Al-Shatnawi, Tariq Qirim, Feras Hawari &amp; Said Alkhatib<br />
Journal title: Journal of Medical Economics<br />
Volume number: 27<br />
Issue number: 1<br />
Pages: 880-886<br />
Year of publication: 2024</p>
<p><span id="more-671"></span></p>
<p style="text-align: center;"><iframe loading="lazy" title="Embedded post" src="https://www.linkedin.com/embed/feed/update/urn:li:share:7234827603474321408" width="504" height="669" frameborder="0" allowfullscreen="allowfullscreen"></iframe></p>
]]></content:encoded>
					
					<wfw:commentRss>https://patheconomics.com/the-hidden-economic-toll-of-tobacco-smoking-and-secondhand-smoke-in-jordan/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Educational Workshop</title>
		<link>https://patheconomics.com/educational-workshop/</link>
					<comments>https://patheconomics.com/educational-workshop/#respond</comments>
		
		<dc:creator><![CDATA[root]]></dc:creator>
		<pubDate>Mon, 19 Aug 2024 21:44:41 +0000</pubDate>
				<category><![CDATA[Events]]></category>
		<guid isPermaLink="false">https://patheconomics.com//?p=575</guid>

					<description><![CDATA[We are glad to collaborate with the J.U.S.T ISPOR chapter and deliver a tour around Path Economics solutions and emerging trends in HEOR sciences. Join us on Tuesday 20 August &#160; &#160;]]></description>
										<content:encoded><![CDATA[<h5 style="direction: ltr; text-align: center;"><span style="color: #000000;"><strong>We are glad to collaborate with the J.U.S.T ISPOR chapter and deliver a tour around Path Economics solutions and emerging trends in HEOR sciences.</strong></span></h5>
<h5 style="direction: ltr; text-align: center;"><span style="color: #000000;"><strong>Join us on Tuesday 20 August</strong></span></h5>
<h5><a href="https://www.linkedin.com/company/path-economics" target="_blank" rel="noopener"><img loading="lazy" decoding="async" class="aligncenter wp-image-581 " src="https://patheconomics.com//wp-content/uploads/2024/08/pikaso_enhance__none_2K_Standard_r_c_-1.jpeg" alt="" width="1113" height="790" srcset="https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__none_2K_Standard_r_c_-1.jpeg 2560w, https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__none_2K_Standard_r_c_-1-300x213.jpeg 300w, https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__none_2K_Standard_r_c_-1-1024x726.jpeg 1024w, https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__none_2K_Standard_r_c_-1-768x545.jpeg 768w, https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__none_2K_Standard_r_c_-1-1536x1090.jpeg 1536w, https://patheconomics.com/wp-content/uploads/2024/08/pikaso_enhance__none_2K_Standard_r_c_-1-2048x1453.jpeg 2048w" sizes="auto, (max-width: 1113px) 100vw, 1113px" /></a></h5>
<p>&nbsp;</p>
<p>&nbsp;</p>
]]></content:encoded>
					
					<wfw:commentRss>https://patheconomics.com/educational-workshop/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Leading Through Innovation: The Future of Pharma Intelligence</title>
		<link>https://patheconomics.com/leading-through-innovation-the-future-of-pharma-intelligence/</link>
					<comments>https://patheconomics.com/leading-through-innovation-the-future-of-pharma-intelligence/#respond</comments>
		
		<dc:creator><![CDATA[root]]></dc:creator>
		<pubDate>Mon, 19 Aug 2024 20:33:05 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Pharma]]></category>
		<guid isPermaLink="false">https://patheconomics.com//?p=564</guid>

					<description><![CDATA[Source of Article: Pi Pharma Intelligence Published Date: July 22, 2024 Introduction As the pharmaceutical landscape continues to evolve, Pi Pharma Intelligence remains at the forefront of innovation. Our dedication to pushing the boundaries of what&#8217;s possible in pharma intelligence has set new industry standards and is reshaping how companies approach healthcare challenges. Innovating at [&#8230;]]]></description>
										<content:encoded><![CDATA[<h4 style="direction: ltr;"><span style="color: #000000;">Source of Article:</span> <a href="https://www.linkedin.com/pulse/leading-through-innovation-future-pharma-intelligence-h7lrc/?trackingId=v7bHU3poog2IqxjWn53IcQ%3D%3D" target="_blank" rel="noopener">Pi Pharma Intelligence</a></h4>
<p style="direction: ltr;">Published Date: July 22, 2024</p>
<h4 style="direction: ltr;"><span style="text-decoration: underline; color: #000000;"><strong>Introduction</strong></span></h4>
<p style="direction: ltr;">As the pharmaceutical landscape continues to evolve, Pi Pharma Intelligence remains at the forefront of innovation. Our dedication to pushing the boundaries of what&#8217;s possible in pharma intelligence has set new industry standards and is reshaping how companies approach healthcare challenges.</p>
<h4 style="direction: ltr;"><span style="text-decoration: underline; color: #000000;"><strong>Innovating at Every Level</strong></span></h4>
<p style="direction: ltr;">Emerging Technologies: At Pi Pharma, we&#8217;re harnessing the power of artificial intelligence and machine learning to enhance our data analysis capabilities. This technology allows us to provide predictive insights that are more accurate and far-reaching than ever before.</p>
<p style="direction: ltr;">Analytical Methodologies: We have developed proprietary algorithms that streamline the data digestion process, making it quicker and more efficient. These methodologies enable us to handle vast amounts of data and extract meaningful insights at an unprecedented pace.</p>
<p style="direction: ltr;">Real-World Application: Our innovative approaches are not just theoretical; they have practical applications that have proven to be game-changers for our clients. From real-time market analysis to personalized drug development strategies, our solutions are tailored to meet the diverse needs of the global pharmaceutical industry.</p>
<h4 style="direction: ltr;"><span style="color: #000000;"><strong><span style="text-decoration: underline;">Impact and Future Directions</span></strong></span></h4>
<p style="direction: ltr;">The impact of our innovations is clear. Clients report improved decision-making processes, faster market adaptation, and enhanced competitive advantage. Looking ahead, Pi Pharma is committed to continuing our investment in innovation, focusing on sustainability and even greater integration of technology in pharmaceutical intelligence.</p>
<h4 style="direction: ltr;"><span style="text-decoration: underline; color: #000000;"><strong>Conclusion</strong></span></h4>
<p style="direction: ltr;">As we lead through innovation, Pi Pharma Intelligence is not just following the trends—we are creating them. Join us on this journey as we explore the limitless possibilities of pharma intelligence and continue to make a significant impact on the industry worldwide.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://patheconomics.com/leading-through-innovation-the-future-of-pharma-intelligence/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
